Chart 2.1.

Recommendations for blood lipid management, recommendation grade, and level of evidence

Recommendation	Recommendation grade	Level of evidence	Reference
Individuals at very high CV risk: LDL-c should be reduced to < 50 mg/dL and non-HDL-c to < 80 mg/dL	I	B	7
Individuals at high CV risk: LDL-c should be reduced to < 70 mg/dL and non-HDL-c to < 100 mg/dL	I	A	7
Individuals at high and very high CV risk: whenever possible and tolerated, give preference to high-intensity statins or Ezetimibe associated with statin (Simvastatin 40 mg or another statin at least as potent)	I	A	7
Individuals at moderate CV risk: LDL-c should be reduced to < 100 mg/dL and non-HDL-c to < 130 mg/dL	I	A	7
Individuals at moderate CV risk: whenever possible and tolerated, give preference to statins of at least moderate intensity	I	A	7
Individuals at low CV risk: the LDL-c target should be < 130 mg/dL and non-HDL-c < 160 mg/dL	I	A	7
Drug therapy to increase HDL-c levels is not recommended	III	A	7
Individuals with TG levels > 500 mg/dL should receive appropriate therapy to reduce the risk for pancreatitis	I	A	7
Individuals with TG levels between 150 and 499 mg/dL should receive therapy based on CV risk and associated conditions	IIa	B	7

CV: cardiovascular; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: triglycerides. The reassessment period after the drug treatment must be of at least a month. Adapted from the Updated Brazilian Guideline for Dyslipidemia and Atherosclerosis Prevention.⁷